SAN DIEGO , Oct. 1, 2020 /PRNewswire/ -- Biocept, Inc . (Nasdaq: BIOC), a leading commercial provider of molecular diagnostic assays, products and services designed to provide physicians with clinically actionable information to improve patient outcomes, announces the upcoming presentation of
SAN DIEGO , Oct. 5, 2020 /PRNewswire/ -- Biocept, Inc . (Nasdaq: BIOC), a leading commercial provider of molecular diagnostic tests and services for physicians treating cancer patients , announces results from a prospective study comparing its Target Selector™ cerebrospinal fluid testing to
SAN DIEGO , Oct. 6, 2020 /PRNewswire/ -- Biocept, Inc . (Nasdaq: BIOC), a leading commercial provider of molecular diagnostic tests and services for physicians treating patients with cancer, announces it has received more than 50,000 COVID-19 specimens to date for processing through its RT-PCR
Diagnostic industry veteran plans immediate start SAN DIEGO , Oct. 21, 2020 /PRNewswire/ -- Biocept, Inc . (Nasdaq: BIOC), a leading commercial provider of molecular diagnostic tests and services, announces the appointment of Samuel D. Riccitelli to its Board of Directors, effective immediately.
SAN DIEGO , Oct. 29, 2020 /PRNewswire/ -- Biocept, Inc . (Nasdaq: BIOC), a leading commercial provider of molecular diagnostic tests and services for physicians treating patients with cancer, announces an update on its COVID-19 testing with more than 80,000 samples received to date for processing
SAN DIEGO , Nov. 4, 2020 /PRNewswire/ -- Biocept, Inc. (Nasdaq: BIOC), a leading commercial provider of molecular diagnostic tests and services for physicians treating cancer patients, announces that it will release financial results for the three and nine months ended September 30, 2020 after the
Biocept further expands its patent estate for capturing and detecting target cells of interest, including CTCs SAN DIEGO , Nov. 5, 2020 /PRNewswire/ -- Biocept, Inc . (Nasdaq: BIOC), a leading commercial provider of molecular diagnostic tests, products and services designed to provide physicians
Further expands global patent estate for capturing and detecting rare cells of interest, including CTCs, to aid in the treatment of patients with cancer SAN DIEGO , Nov. 9, 2020 /PRNewswire/ -- Biocept, Inc . (NASDAQ: BIOC), a leading commercial provider of molecular diagnostic assays, products
SAN DIEGO , Nov. 12, 2020 /PRNewswire/ -- Biocept, Inc . (Nasdaq: BIOC), a leading commercial provider of molecular diagnostic tests and services for physicians treating patients with cancer, announces an update on its COVID-19 testing with more than 100,000 samples received to date for processing
Revenues of $6.6 million - a result of decision to offer COVID-19 testing Conference call begins at 4:30 p.m. Eastern time today SAN DIEGO , Nov. 12, 2020 /PRNewswire/ -- Biocept, Inc. (Nasdaq: BIOC), a leading commercial provider of molecular diagnostic assays, products and services designed to
